PDL BioPharma, Inc. Net Income Common

Net Income Common of PDLI for past 10 years: annual, quarterly and twelve month trailing (TTM) including Net Income Common growth rates and interactive chart. Net income to common (NIC), also called net profit to shareholders, is calculated as sales minus cost of goods sold, selling, general and administrative expenses, operating expenses, depreciation, interest, taxes, and other expenses incuding preferred dividends. It is a useful number for investors to assess how much revenue exceeds the expenses of an organization.


Highlights and Quick Summary

  • Net Income Common for the quarter ending June 29, 2020 was $-50 Million (a 57.52% increase compared to previous quarter)
  • Year-over-year quarterly Net Income Common increased by 180.99%
  • Annual Net Income Common for 2019 was $-70.4 Million (a 2.25% increase from previous year)
  • Annual Net Income Common for 2018 was $-68.9 Million (a -162.18% decrease from previous year)
  • Annual Net Income Common for 2017 was $111 Million (a 74.12% increase from previous year)
  • Twelve month Net Income Common ending June 29, 2020 was $-154 Million (a 41.86% increase compared to previous quarter)
  • Twelve month trailing Net Income Common decreased by -20518.78% year-over-year
Trailing Net Income Common for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$-154 Million $-109 Million $-70.4 Million $756 Thousand
Visit stockrow.com/PDLI for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Net Income Common of PDL BioPharma, Inc.

Most recent Net Income Commonof PDLI including historical data for past 10 years.

Interactive Chart of Net Income Common of PDL BioPharma, Inc.

PDL BioPharma, Inc. Net Income Common for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-49.97 $-31.72
2019 $-54.89 $-17.78 $-4.42 $6.68 $-70.41
2018 $16.28 $25.56 $-112.3 $1.6 $-68.86
2017 $22.34 $20.73 $60.44 $7.24 $110.75
2016 $-10.34 $13.91 $4.15 $55.89 $63.61
2015 $100.57 $69.46 $78.26 $84.5 $332.8
2014 $55.07 $102.24 $92.06 $72.88 $322.24
2013 $61.09 $56.23 $93.74 $53.47 $264.53
2012 $49.41 $48.58 $73.5 $40.18 $211.67
2011 $38.94 $45.92 $69.99 $44.55 $199.39
2010 $-24.46 $40.19 $50.14 $91.87

Business Profile of PDL BioPharma, Inc.

Sector: Other
Industry: Other
PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.